Get the Stockscreener App
144.88
0.37%
0.54
Pre-market:
144.48
-0.40
-0.28%
Repligen Corp stock is traded at $144.88, with a volume of 796.76K.
It is up +0.37% in the last 24 hours and down -3.88% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$144.34
Open:
$144.12
24h Volume:
796.76K
Relative Volume:
1.37
Market Cap:
$8.13B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-467.35
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-0.34%
1M Performance:
-3.88%
6M Performance:
-0.62%
1Y Performance:
-27.08%
1-Day Range:
$138.01
$146.60
1-Week Range:
$138.01
$153.89
52-Week Range:
$113.50
$200.23
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
144.88 | 8.13B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
492.06 | 176.29B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
231.79 | 66.56B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
90.87 | 44.95B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
222.05 | 32.62B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.09 | 17.41B | 17.28B | 108.00M | 391.00M | 0.20 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Repligen Corp director Hunt Anthony sells $4.08 million in stock By Investing.com - Investing.com South Africa
Repligen Corp director Hunt Anthony sells $4.08 million in stock - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth and valuation challenges - Investing.com
Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Evercore ISI - Defense World
Repligen Co. (NASDAQ:RGEN) Shares Sold by Victory Capital Management Inc. - Defense World
Repligen director Pax Margaret acquires $37,672 in common stock By Investing.com - Investing.com South Africa
REPLIGEN Director Margaret Pax Acquires 250 Shares - TradingView
Evercore ISI sets Repligen stock In Line with $155 price target - Investing.com
Demystifying Repligen: Insights From 6 Analyst Reviews - Benzinga
Repligen initiated with an In Line at Evercore ISI - TipRanks
Repligen Corp (RGEN) Shares Up 5.72% on Mar 17 - GuruFocus.com
Repligen Corp (RGEN) Shares Up 5.72% on Mar 15 - GuruFocus.com
REPLIGEN CORP SEC 10-K Report - TradingView
William Blair Brokers Reduce Earnings Estimates for Repligen - Defense World
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack - The Globe and Mail
Oppenheimer & Co. Inc. Purchases New Shares in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corporation’s Acquisition of Bioprocessing PAT Device Portfolio from 908 Devices - Global Legal Chronicle
US Bancorp DE Raises Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen buying 908 Devices’ Bioprocess Analytics portfolio - BioWorld Online
Sanctuary Advisors LLC Sells 268 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World
Truist Financial Corp Trims Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - AOL
Leerink maintains Repligen stock Outperform rating, $200 target - Investing.com
908 Devices stock jumps on Repligen deal (RGEN:NASDAQ) - Seeking Alpha
Repligen acquires 908 Devices’ desktop bioprocessing tech - Investing.com
Repligen acquires 908 Devices’ desktop bioprocessing tech By Investing.com - Investing.com Canada
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Yahoo Finance
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Armenian Reporter
Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Global Retirement Partners LLC Has $53,000 Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Global Hollow Fiber Filtration Market: A Comprehensive Study - openPR
CIBC Asset Management Inc Acquires 81 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Principal Financial Group Inc. Decreases Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen’s SWOT analysis: bioprocessing leader’s stock poised for growth - Investing.com
Repligen stock holds steady after Benchmark maintains rating - Investing.com
Repligen stock holds steady after Benchmark maintains rating By Investing.com - Investing.com UK
Repligen (NASDAQ:RGEN) Price Target Raised to $200.00 - Defense World
Repligen (NASDAQ:RGEN) Price Target Raised to $205.00 - Armenian Reporter
Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Repligen (NASDAQ:RGEN) Earns Buy Rating from HC Wainwright - Defense World
Repligen (NASDAQ:RGEN) Shares Up 8.1% Following Strong Earnings - Defense World
Repligen Earnings: Encouraging Guidance Supports Attractive Growth Story - Morningstar
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Repligen (RGEN) Beats Q4 Earnings Estimates - MSN
Repligen's Q4 Earnings Beat Estimates, Revenues In Line - Yahoo Finance
The Analyst Verdict: Repligen In The Eyes Of 4 Experts - Benzinga
H.C. Wainwright maintains Buy on Repligen, target at $180 - Investing.com
Repligen Corporation (NASDAQ:RGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Canaccord raises Repligen stock target to $170, maintains Hold - Investing.com
KeyBanc maintains Repligen stock with $220 target following Q4 results - Investing.com
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):